Pituitary & hypothalamus

Management of water and electrolyte disorders post-pituitary adenoma surgery: experience with Tolvaptan 7.5 mg at a tertiary care centre

PituitaryPublished Retrospective cohort study

Authors' conclusion

Tolvaptan 7.5 mg may serve as an effective alternative treatment modality in moderate-to-severe SIAD patients.

Study context

Population
Patients with water and electrolyte disorders after pituitary adenoma surgery at a tertiary care centre; median age 30 years, 69.5% female, 62.1% macroadenoma, CD 54.8%
Participants
82 patients
Outcome
Frequency of water and electrolyte disorders
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Isolated arginine vasopressin deficiency (AVP-D)
40.2%
Isolated syndrome of inappropriate antidiuresis (SIAD)
39%
Biphasic response
18.2%
Triphasic response
1.2%
Cerebral salt wasting
1.2%

Observational data: associations, not effects.

Further findings

OutcomeValues
Serum sodium with tolvaptan 7.5 mg · 24 hoursTolvaptan 7.5 mg median 5 (range 2–9) mEq/L · baseline serum sodium at initiation (median) 127 (125-130) mEq/L
Serum sodium with tolvaptan 7.5 mg — Doses of oral tolvaptan 7.5 mg given to 13 patients
25
Serum sodium with tolvaptan 7.5 mg — Correlation of correction with baseline sodium
r=−0.29, p = 0.15
Serum sodium with tolvaptan 7.5 mg — Trend toward higher correction with later postoperative use
r = 0.34, p = 0.09
  • Serum sodium with tolvaptan 7.5 mg: 24-hour increment

Median onset of AVP-D and SIAD

AVP-D onset, post-operative day
1
SIAD onset, post-operative day
4
Correlation of day of SIAD onset with its duration
r=−0.43, 0.002
  • Inverse correlation

Safety

Overcorrection (>10 mEq/L/24 h) after tolvaptan

Overcorrection (> 10 mEq/L/24 h)
2 patients (15.3%)
Osmotic demyelination
0

Original publication

Management of water and electrolyte disorders post-pituitary adenoma surgery: experience with Tolvaptan 7.5 mg at a tertiary care centre. Pituitary. Published 28 October 2025. doi:10.1007/s11102-025-01592-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.